U.S. Markets close in 5 hrs 37 mins

Pharma companies Amarin, Nektar Therapeutics nosedive on product concerns

Amarin shares are plunging after the biotech company revealed the FDA will proceed with a review of its heart drug. This coming as Nektar Therapeutics is sliding after it disclosed a quality control issue with a key cancer therapy. Yahoo Finance's Jared Blikre joins Akiko Fujita on 'The Ticker' to discuss.